The Convoluted Wellness Movement
Say what you will about RFK Jr, but his ideas, if implemented even in some small ways, would have a drastic impact on the psychopharmaceutical industry. I'm a therapist myself, and I can't tell you how many teenagers are placed on SSRIs and ADHD medication without careful consideration for long term effects. Not that these medications are poisonous - they can be very helpful for many. I do think they are overprescribed, however, and can lead to lifelong dependency if not used carefully or with intent. While I don't think psychedelics would be great for teenagers and their developing brains (says the guy who took mushrooms for the first time at 17), I do think they are a powerful alternative, and do not require as much consistent dosing. The pharmaceutical industry will try to push microdosing, so as to make greater profits.
Do I think psychedelics will be implemented as mental health treatment successfully on the first go-around? Not necessarily. Do I think that certain people with a family history of psychosis and mood disorders should avoid psychedelics? Probably.
The companies at the forefront of this research could be in a decent position to spike in value. They may be eventually bought out by other entities, of course, or simply lose their speculative value. Maybe this is already happening. I'm wondering if CYBIN in particular, is forming a bottom here. It does look trapped in an endless wedge, with every pump getting aggressively sold. However, volume is steadily increasing week by week, which could indicate some hidden accumulation.
MindMedicine may be positioned a little better, from a technical perspective. I've bought back into both MindMedicine and Cybin equally over the last day or two. Not a big position, but perhaps worth the gamble. Each could easily decline by 50% or more from here. MNDMD at least seems to have a healthier chart.
The bigger concern is whether these companies' finances can withstand more time before regulatory clarity, as well as governmental stability as a whole. Things are looking very strange in the U.S. Either way, there is a movement (public or not) towards homeopathic medicine.
I guess we'll see. This investment is entirely speculative, and seems just as likely to trend towards zero as it is to explode 10x in value.
This is my personal opinion, and is meant for personal use only - not as financial advice. These stocks have relatively low volume and are prone to wild price swings.
Do I think psychedelics will be implemented as mental health treatment successfully on the first go-around? Not necessarily. Do I think that certain people with a family history of psychosis and mood disorders should avoid psychedelics? Probably.
The companies at the forefront of this research could be in a decent position to spike in value. They may be eventually bought out by other entities, of course, or simply lose their speculative value. Maybe this is already happening. I'm wondering if CYBIN in particular, is forming a bottom here. It does look trapped in an endless wedge, with every pump getting aggressively sold. However, volume is steadily increasing week by week, which could indicate some hidden accumulation.
MindMedicine may be positioned a little better, from a technical perspective. I've bought back into both MindMedicine and Cybin equally over the last day or two. Not a big position, but perhaps worth the gamble. Each could easily decline by 50% or more from here. MNDMD at least seems to have a healthier chart.
The bigger concern is whether these companies' finances can withstand more time before regulatory clarity, as well as governmental stability as a whole. Things are looking very strange in the U.S. Either way, there is a movement (public or not) towards homeopathic medicine.
I guess we'll see. This investment is entirely speculative, and seems just as likely to trend towards zero as it is to explode 10x in value.
This is my personal opinion, and is meant for personal use only - not as financial advice. These stocks have relatively low volume and are prone to wild price swings.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.